Dr Kuykendall
Cervantes F et al. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: The REALISE phase 2 study. Leukemia 2021;35(12):3455-65. Abstract
Harrison CN et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): Results from a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol 2024;11(10):e729-e740. Abstract
Harrison CN et al. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. Br J Haematol 2022;198(2):317-27. Abstract
Harrison CN et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol 2020;95(6):594-603. Abstract
Lin JQ et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol 2022;86(2):339-44. Abstract
Lussana F et al. Ruxolitinib-associated infections: A systematic review and meta-analysis. Am J Hematol 2018;93(3):339-47. Abstract
Mollé N et al. Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. Blood 2020;135(13):1062-66. Abstract
Pardanani A et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol 2015;1(5):643-51. Abstract
Sapre M et al. Metabolic effects of JAK1/2 inhibition in patients with myeloproliferative neoplasms. Sci Rep 2019;9(1):16609. Abstract
Dr Bose
Bewersdorf J et al. Spleen volume reduction predicts survival in myelofibrosis patients on pacritinib but not best available therapy: PERSIST-2 landmark overall survival analysis. EHA 2023;Abstract P1030.
Chifotides HT et al. Association of myelofibrosis phenotypes with clinical manifestations, molecular profiles, and treatments. Cancers (Basel) 2023;15(13):3331. Abstract
Mascarenhas J et al. A retrospective head-to-head comparison between pacritinib and ruxolitinib in patients with myelofibrosis and moderate to severe thrombocytopenia. Blood 2021;138(Suppl 1):3639. Abstract
Mascarenhas J et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. JAMA Oncol 2018;4(5):652-59. Abstract
Mesa RA et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial. Lancet Haematol 2017;4(5):e225-e236. Abstract
Oh ST et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 2023;7(19):5835-42. Abstract
Oh ST et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. ASH 2022;Abstract 628.
Vachhani P et al. Efficacy of pacritinib in patients with myelofibrosis who have overlapping thrombocytopenia and anemia. EHA 2024;Abstract P1037.
Verstovsek S et al. MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. EHA 2022;Abstract S195.
Dr Yacoub
Gerds AT et al. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv 2024;8(17):4511-22. Abstract
Harrison CN et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomised, open-label, phase 3 trial. Lancet Haematol 2018;5(2):e73-e81. Abstract
Mesa RA et al. MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. ASCO 2022;Abstract 7002.
Mesa RA et al. SIMPLIFY-1: A phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol 2017;35(34):3844-50. Abstract
Verstovsek S et al. Momelotinib long-term safety and survival in myelofibrosis: Integrated analysis of phase 3 randomized controlled trials. Blood Adv 2023;7(14):3582-91. Abstract
Verstovsek S et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 2023;401(10373):269-80. Abstract
Verstovsek S et al. Robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor naïve and previously JAK inhibitor treated intermediate/high risk myelofibrosis patients. ASH 2020;Abstract 54.
Dr Fleischman
Ali H et al. A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis. AACR 2023;Abstract CT261.
Ali H et al. Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034. ASCO 2023;Abstract 7063.
Harrison CN et al. Phase III MANIFEST-2: Pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future Oncol 2022;18(27):2987-97. Abstract
Mascarenhas J et al. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncol 2022;18(22):2393-402. Abstract
Mascarenhas J et al. Favorable overall survival with imetelstat treatment correlates with other clinical benefits in intermediate 2 or high risk myelofibrosis relapsed/refractory to Janus kinase inhibitor. EHA 2020;Abstract EP1107.
Mascarenhas J et al. Imetelstat is effective treatment for patients with intermediate-2 or high-risk myelofibrosis who have relapsed on or are refractory to Janus kinase inhibitor therapy: Results of a phase 2 randomized study of two dose levels. ASH 2018;Abstract 685.
Pemmaraju N et al. Transform-1: A randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis. ASH 2023;Abstract 620.
Rampal R et al. Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis. ASCO 2024;Abstract 6502.
Ross DM et al. Identifying disease-modifying potential in myelofibrosis clinical trials. Blood 2024 Oct 17;144(16):1679-1688. Abstract
Tantravahi SK et al. Long-term response to selinexor in patients with myelofibrosis and refractory or intolerant to JAK inhibitors: Follow-up results of a single-center, phase II, investigator-initiated trial (IIT). SOHO 2024;Abstract MPN-652.